Applied Genetic Technologies (NASDAQ:AGTC) reported Q2 2018 earnings this Afternoon, coming in at ($0.29) per share, missing Wall Street’s estimates of ($0.09) per Share. Revenue for the quarter came in at $4.85 million missing the streets estimates of $8.72 million Recent Insider Trading for Applied Genetic Technologies (NASDAQ:AGTC)
- On 11/16/2016 Ivana Magovcevic, Director, bought 3,000 with an average share price of $9.63 per share and the total transaction amounting to $28,890.00.
- On 11/1/2016 Jeffrey D Chulay, VP, sold 1,000 with an average share price of $7.05 per share and the total transaction amounting to $7,050.00.
- On 9/22/2016 Mark S Shearman, Insider, bought 3,000 with an average share price of $8.87 per share and the total transaction amounting to $26,610.00.
- On 9/20/2016 Stephen W Potter, Insider, bought 1,400 with an average share price of $8.89 per share and the total transaction amounting to $12,446.00.
- On 9/19/2016 Lawrence E Bullock, CFO, bought 10,000 with an average share price of $8.75 per share and the total transaction amounting to $87,500.00.
- On 2/23/2015 Plc Glaxosmithkline, Major Shareholder, sold 503,150 with an average share price of $22.00 per share and the total transaction amounting to $11,069,300.00.
Recent Trading for Applied Genetic Technologies (NASDAQ:AGTC) Shares of Applied Genetic Technologies closed the previous trading session at 4.25 +0.00 0.00% with 4.349999904632568 shares trading hands.